CoChat
Sign Up
Cited by 185

The DOI matches its Crossref record.

Adenoviral Vector Immunity: Its Implications and Circumvention Strategies

S. Ahi, Yadvinder, S. Bangari, Dinesh, K. Mittal, Suresh·2011·Current Gene Therapy
DOI 10.2174/156652311796150372PMC PMC4009923
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/156652311796150372

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 224

  1. [1]Paielli DL Wing MS Rogulski KR Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse Mol Ther 2000 1 263 274 10933942
  2. [2]Bangari DS Mittal SK Porcine adenoviral vectors evade preexisting humoral immunity to adenoviruses and efficiently infect both human and murine cells in culture Virus Res 2004 105 127 136 15351486
  3. [3]Xiang Z Li Y Cun A Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa Emerg Infect Dis 2006 12 1596 1599 17176582 PMC3290939
  4. [4]Harvey BG Worgall S Ely S Leopold PL Crystal RG Cellular immune responses of healthy individuals to intradermal administration of an E1–E3- adenovirus gene transfer vector Hum Gene Ther 1999 10 2823 2837 10584928
  5. [5]Dai Y Schwarz EM Gu D Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression Proc Natl Acad Sci USA 1995 92 1401 1405 7877990 PMC42527
  6. [6]Elkon KB Liu CC Gall JG Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors Proc Natl Acad Sci USA 1997 94 9814 9819 9275208 PMC23274
  7. [7]Kafri T Morgan D Krahl T Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy Proc Natl Acad Sci USA 1998 95 11377 11382 9736744 PMC21650
  8. [8]Yang Y Nunes FA Berencsi K Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy Proc Natl Acad Sci USA 1994 91 4407 4411 8183921 PMC43794
  9. [9]Yang Y Li Q Ertl HC Wilson JM Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses J Virol 1995 69 2004 2015 7884845 PMC188865
  10. [10]Toogood CI Crompton J Hay RT Antipeptide antisera define neutralizing epitopes on the adenovirus hexon J Gen Virol 1992 73 Pt 6 1429 1435 1376769
  11. [11]Mittal SK McDermott MR Johnson DC Prevec L Graham FL Monitoring foreign gene expression by a human adenovirus-based vector using the firefly luciferase gene as a reporter Virus Res 1993 28 67 90 8388142
  12. [12]Dong JY Wang D Van Ginkel FW Pascual DW Frizzell RA Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus vector Hum Gene Ther 1996 7 319 331 8835219
  13. [13]Moffatt S Hays J HogenEsch H Mittal SK Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: implications in gene therapy Virology 2000 272 159 167 10873758
  14. [14]Sailaja G HogenEsch H North A Hays J Mittal SK Encapsulation of recombinant adenovirus into alginate microspheres circumvents vector-specific immune response Gene Ther 2002 9 1722 1729 12457287 PMC1459421
  15. [15]Walter J You Q Hagstrom JN Sands M High KA Successful expression of human factor IX following repeat administration of adenoviral vector in mice Proc Natl Acad Sci USA 1996 93 3056 3061 8610167 PMC39760
  16. [16]Vlachaki MT Hernandez-Garcia A Ittmann M Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model Mol Ther 2002 6 342 348 12231170
  17. [17]Varnavski AN Zhang Y Schnell M Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity J Virol 2002 76 5711 5719 11991999 PMC137042
  18. [18]Varnavski AN Calcedo R Bove M Gao G Wilson JM Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and pre-immunized mice Gene Ther 2005 12 427 436 15647774
  19. [19]Perreau M Pantaleo G Kremer EJ Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells J Exp Med 2008 205 2717 2725 18981239 PMC2585831
  20. [20]Zaiss AK Vilaysane A Cotter MJ Antiviral antibodies target adenovirus to phagolysosomes and amplify the innate immune response J Immunol 2009 182 7058 7068 19454703
  21. [21]Tang J Olive M Pulmanausahakul R Human CD8+ cytotoxic T cell responses to adenovirus capsid proteins Virology 2006 350 312 322 16499941
  22. [22]Olive M Eisenlohr L Flomenberg N Hsu S Flomenberg P The adenovirus capsid protein hexon contains a highly conserved human CD4+ T-cell epitope Hum Gene Ther 2002 13 1167 1178 12133270
  23. [23]Crystal RG Transfer of genes to humans: early lessons and obstacles to success Science 1995 20 270 404 410 7569994
  24. [24]Appledorn DM McBride A Seregin S Complex interactions with several arms of the complement system dictate innate and humoral immunity to adenoviral vectors Gene Ther 2008 15 1606 1617 18615115 PMC11112971
  25. [25]Tian J Xu Z Smith JS Adenovirus activates complement by distinctly different mechanisms in vitro and in vivo: indirect complement activation by virions in vivo J Virol 2009 83 5648 5658 19321608 PMC2681959
  26. [26]Xu Z Tian J Smith JS Byrnes AP Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement J Virol 2008 82 11705 11713 18815305 PMC2583672
  27. [27]Kiang A Hartman ZC Everett RS Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system Mol Ther 2006 14 588 598 16733096
  28. [28]Greig JA Buckley SM Waddington SN Influence of coagulation factor x on in vitro and in vivo gene delivery by adenovirus (Ad) 5, Ad35, and chimeric Ad5/Ad35 vectors Mol Ther 2009 17 1683 1691 19603000 PMC2835023
  29. [29]Parker AL Waddington SN Nicol CG Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes Blood 2006 108 2554 2561 16788098
  30. [30]Shayakhmetov DM Gaggar A Ni S Li ZY Lieber A Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity J Virol 2005 79 7478 7491 15919903 PMC1143681
  31. [31]Rhee EG Blattman JN Kasturi SP Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors J Virol 2011 85 315 323 20962088 PMC3014160
  32. [32]Jiang H Wang Z Serra D Frank MM Amalfitano A Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-ad antibodies Mol Ther 2004 10 1140 1142 15564145
  33. [33]Cichon G Boeckh-Herwig S Schmidt HH Complement activation by recombinant adenoviruses Gene Therapy 2001 8 1794 1800 11803399 PMC7091591
  34. [34]Cerullo V Seiler MP Mane V Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors Mol Ther 2007 15 378 385 17235317
  35. [35]Zaiss AK Liu Q Bowen GP Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors J Virol 2002 76 4580 4590 11932423 PMC155101
  36. [36]Segura MM Alba R Bosch A Chillon M Advances in helper-dependent adenoviral vector research Current Gene Therapy 2008 8 222 235 18691018
  37. [37]Liu Q Zaiss AK Colarusso P The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors Hum Gene Ther 2003 14 627 643 12804145
  38. [38]Brenner M Gene transfer by adenovectors Blood 1999 94 3965 3967 10590039
  39. [39]Seiler MP Cerullo V Lee B Immune response to helper dependent adenoviral mediated liver gene therapy: challenges and prospects Curr Gene Ther 2007 7 297 305 17979676
  40. [40]Schiedner G Bloch W Hertel S A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells Hum Gene Ther 2003 14 1631 1641 14633405
  41. [41]Wolins N Lozier J Eggerman TL Intravenous administration of replication-incompetent adenovirus to rhesus monkeys induces thrombocytopenia by increasing in vivo platelet clearance Br J Haematol 2003 123 903 905 14632782
  42. [42]Morral N O'Neal WK Rice K Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons Hum Gene Ther 2002 13 143 154 11779418
  43. [43]Schnell MA Zhang Y Tazelaar J Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors Mol Ther 2001 3 708 722 11356076
  44. [44]Zhang Y Chirmule N Gao GP Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages Mol Ther 2001 3 697 707 11356075
  45. [45]Smith JS Tian J Muller J Byrnes AP Unexpected pulmonary uptake of adenovirus vectors in animals with chronic liver disease Gene Ther 2004 11 431 438 14973536
  46. [46]Smith JS Tian J Lozier JN Byrnes AP Severe pulmonary pathology after intravenous administration of vectors in cirrhotic rats Mol Ther 2004 9 932 941 15194060
  47. [47]Stilwell JL McCarty DM Negishi A Superfine R Samulski RJ Development and characterization of novel empty adenovirus capsids and their impact on cellular gene expression J Virol 2003 77 12881 12885 14610209 PMC262574
  48. [48]Bramson JL Hitt M Gauldie J Graham FL Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination Gene Ther 1997 4 1069 1076 9415313
  49. [49]Nagao S Kuriyama S Okuda H Adenovirus-mediated gene transfer into tumors: evaluation of direct readministration of an adenoviral vector into subcutaneous tumors of immunocompetent mice Int J Oncol 2001 18 57 65 11115539
  50. [50]Nunes FA Furth EE Wilson JM Raper SE Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: safety of readministration Hum Gene Ther 1999 10 2515 2526 10543616
  51. [51]Brunetti-Pierri N Ng P Progress towards liver and lung-directed gene therapy with helper-dependent adenoviral vectors Curr Gene Ther 2009 9 329 340 19860648
  52. [52]Wilmott RW Amin RS Perez CR Safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lungs of nonhuman primates Hum Gene Ther 1996 7 301 318 8835218
  53. [53]Ginsberg HS Moldawer LL Sehgal PB A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia Proc Natl Acad Sci U S A 1991 88 1651 1655 1848005 PMC51082
  54. [54]Prince GA Porter DD Jenson AB Pathogenesis of adenovirus type 5 pneumonia in cotton rats (Sigmodon hispidus) J Virol 1993 67 101 111 8380066 PMC237342
  55. [55]Li Y Shao JY Liu RY Evaluation of long-term toxicity of Ad/hIFN-gamma, an adenoviral vector encoding the human interferon-gamma gene, in nonhuman primates Human Gene Therapy 2008 19 827 839 18666838
  56. [56]Huang BJ Liu RY Huang JL Long-term toxicity studies in canine of E10A, an adenoviral vector for human endostatin gene Human Gene Therapy 2007 18 207 221 17346097
  57. [57]Maione D Della RC Giannetti P An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus Proc Natl Acad Sci USA 2001 98 5986 5991 11353820 PMC33410
  58. [58]Seregin SS Appledorn DM McBride AJ Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy Mol Ther 2009 17 685 696 19174760 PMC2835110
  59. [59]Thomas MA Spencer JF Toth K Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model Mol Ther 2008 16 1665 1673 18665155 PMC3437752
  60. [60]Smith TA White BD Gardner JM Kaleko M McClelland A Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector Gene Ther 1996 3 496 502 8789799
  61. [61]Kaplan JM Smith AE Transient immunosuppression with deoxyspergualin improves longevity of transgene expression and ability to readminister adenoviral vector to the mouse lung Hum Gene Ther 1997 8 1095 1104 9189767
  62. [62]Ilan Y Jona VK Sengupta K Transient immunosuppression with FK506 permits long-term expression of therapeutic genes introduced into the liver using recombinant adenoviruses in the rat Hepatology 1997 26 949 956 9328318
  63. [63]Guerette B Vilquin JT Gingras M Prevention of immune reactions triggered by first-generation adenoviral vectors by monoclonal antibodies and CTLA4Ig Hum Gene Ther 1996 7 1455 1463 8844205
  64. [64]Jooss K Turka LA Wilson JM Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig Gene Ther 1998 5 309 319 9614550
  65. [65]Ye X Robinson MB Pabin C Batshaw ML Wilson JM Transient depletion of CD4 lymphocyte improves efficacy of repeated administration of recombinant adenovirus in the ornithine transcarbamylase deficient sparse fur mouse Gene Ther 2000 7 1761 1767 11083498
  66. [66]Chirmule N Raper SE Burkly L Readministration of adenovirus vector in nonhuman primate lungs by blockade of CD40-CD40 ligand interactions J Virol 2000 74 3345 3352 10708452 PMC111836
  67. [67]Haegel-Kronenberger H Haanstra K Ziller-Remy C Inhibition of costimulation allows for repeated systemic administration of adenoviral vector in rhesus monkeys Gene Ther 2004 11 241 252 14737083
  68. [68]Ilan Y Sauter B Chowdhury NR Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenoviruses Hepatology 1998 27 1368 1376 9581693
  69. [69]Fontanellas A Hervas-Stubbs S Mauleon I Intensive pharmacological immunosuppression allows for repetitive liver gene transfer with recombinant adenovirus in nonhuman primates Mol Ther 2010 18 754 765 20087317 PMC2862529
  70. [70]Dhar D Spencer JF Toth K Wold WS Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model Mol Ther 2009 17 1724 1732 19602998 PMC2835003
  71. [71]Peng Y Trevejo J Zhou J Inhibition of tumor necrosis factor alpha by an adenovirus-encoded soluble fusion protein extends transgene expression in the liver and lung J Virol 1999 73 5098 5109 10233973 PMC112555
  72. [72]Benihoud K Esselin S Descamps D Respective roles of TNF-alpha and IL-6 in the immune response-elicited by adenovirus-mediated gene transfer in mice Gene Ther 2007 14 533 544 17109009
  73. [73]Wilderman MJ Kim S Gillespie CT Blockade of TNF-alpha decreases both inflammation and efficacy of intrapulmonary Ad.IFNbeta immunotherapy in an orthotopic model of bronchogenic lung cancer Mol Ther 2006 13 910 917 16488193
  74. [74]Sakurai H Tashiro K Kawabata K Adenoviral expression of suppressor of cytokine signaling-1 reduces adenovirus vector-induced innate immune responses J Immunol 2008 180 4931 4938 18354218
  75. [75]Shayakhmetov DM Li ZY Ni S Lieber A Interference with the IL-1-signaling pathway improves the toxicity profile of systemically applied adenovirus vectors J Immunol 2005 174 7310 7319 15905578
  76. [76]Worgall S Leopold PL Wolff G Role of alveolar macrophages in rapid elimination of adenovirus vectors administered to the epithelial surface of the respiratory tract Hum Gene Ther 1997 8 1675 1684 9322870
  77. [77]Lieber A He CY Meuse L The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors J Virol 1997 71 8798 8807 9343240 PMC192346
  78. [78]Kuzmin AI Finegold MJ Eisensmith RC Macrophage depletion increases the safety, efficacy and persistence of adenovirus-mediated gene transfer in vivo Gene Therapy 1997 4 309 316 9176516
  79. [79]Schiedner G Hertel S Johnston M Selective depletion or blockade of Kupffer cells leads to enhanced and prolonged hepatic transgene expression using high-capacity adenoviral vectors Mol Ther 2003 7 35 43 12573616
  80. [80]Shashkova EV Doronin K Senac JS Barry MA Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus Cancer Res 2008 68 5896 5904 18632644
  81. [81]Haisma HJ Kamps JA Kamps GK Polyinosinic acid enhances delivery of adenovirus vectors in vivo by preventing sequestration in liver macrophages J Gen Virol 2008 89 1097 1105 18420786
  82. [82]Haisma HJ Boesjes M Beerens AM Scavenger receptor A: a new route for adenovirus 5 Mol Pharm 2009 6 366 374 19227971
  83. [83]Stone D Liu Y Shayakhmetov D Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver J Virol 2007 81 4866 4871 17301138 PMC1900148
  84. [84]Kreppel F Kochanek S Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide Mol Ther 2008 16 16 29 17912234
  85. [85]Croyle MA Yu QC Wilson JM Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions Hum Gene Ther 2000 11 1713 1722 10954905
  86. [86]Croyle MA Chirmule N Zhang Y Wilson JM PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver Hum Gene Ther 2002 13 1887 1900 12396620
  87. [87]Lanciotti J Song A Doukas J Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates Molecular Therapy 2003 8 99 107 12842433
  88. [88]O'Riordan CR Lachapelle A Delgado C PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo Hum Gene Ther 1999 10 1349 1358 10365665
  89. [89]Fisher KD Stallwood Y Green NK Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies Gene Ther 2001 8 341 348 11313809
  90. [90]Espenlaub S Wortmann A Engler T Reductive amination as a strategy to reduce adenovirus vector promiscuity by chemical capsid modification with large polysaccharides J Gene Med 2008 10 1303 1314 18837065
  91. [91]Eto Y Yoshioka Y Ishida T Optimized PEGylated adenovirus vector reduces the anti-vector humoral immune response against adenovirus and induces a therapeutic effect against metastatic lung cancer Biol Pharm Bull 2010 33 1540 1544 20823571
  92. [92]Eto Y Gao JQ Sekiguchi F PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability J Gene Med 2005 7 604 612 15543536
  93. [93]Croyle MA Chirmule N Zhang Y Wilson JM "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung J Virol 2001 75 4792 4801 11312351 PMC114234
  94. [94]Geest BD Snoeys J Linthout SV Lievens J Collen D Elimination of Innate Immune Responses and Liver Inflammation by PEGylation of Adenoviral Vectors and Methylprednisolone Hum Gene Ther 2005 16 1439 1451 16390275
  95. [95]Mok H Palmer DJ Ng P Barry MA Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses Molecular Therapy 2005 11 66 79 15585407
  96. [96]Croyle MA Le HT Linse KD PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile Gene Ther 2005 12 579 587 15647765
  97. [97]Wortmann A Vohringer S Engler T Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies Mol Ther 2008 16 154 162 17848961
  98. [98]Park JW Mok H Park TG Epidermal growth factor (EGF) receptor targeted delivery of PEGylated adenovirus Biochem Biophys Res Commun 2008 366 769 774 18083120
  99. [99]Jung Y Park HJ Kim PH Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells J Control Release 2007 123 164 171 17854941
  100. [100]Ogawara K Rots MG Kok RJ A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo Hum Gene Ther 2004 15 433 443 15144574
  101. [101]Morrison J Briggs SS Green NK Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer Hum Gene Ther 2009 20 239 251 19257852
  102. [102]Green NK Morrison J Hale S Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer J Gene Med 2008 10 280 289 18214996
  103. [103]Green NK Herbert CW Hale SJ Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus Gene Ther 2004 11 1256 1263 15215884
  104. [104]Bergelson JM Cunningham JA Droguett G Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5 Science 1997 275 1320 1323 9036860
  105. [105]Tomko RP Xu R Philipson L HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses Proc Natl Acad Sci USA 1997 94 3352 3356 9096397 PMC20373
  106. [106]Roelvink PW Lizonova A Lee JG The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F J Virol 1998 72 7909 7915 9733828 PMC110119
  107. [107]Gaggar A Shayakhmetov DM Lieber A CD46 is a cellular receptor for group B adenoviruses Nat Med 2003 9 1408 1412 14566335
  108. [108]Tuve S Wang H Ware C A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells J Virol 2006 80 12109 12120 17020944 PMC1676274
  109. [109]Short JJ Pereboev AV Kawakami Y Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors Virology 2004 322 349 359 15110532
  110. [110]Hong SS Karayan L Tournier J Curiel DT Boulanger PA Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells EMBO J 1997 16 2294 2306 9171344 PMC1169831
  111. [111]Smith KD Andersen-Nissen E Hayashi F Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility Nat Immunol 2003 4 1247 1253 14625549
  112. [112]Arnberg N Edlund K Kidd AH Wadell G Adenovirus type 37 uses sialic acid as a cellular receptor J Virol 2000 74 42 48 10590089 PMC111511
  113. [113]Wickham TJ Mathias P Cheresh DA Nemerow GR Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment Cell 1993 73 309 319 8477447
  114. [114]Bai M Harfe B Freimuth P Mutations that alter an Arg-Gly-Asp (RGD) sequence in the adenovirus type 2 penton base protein abolish its cell-rounding activity and delay virus reproduction in flat cells J Virol 1993 67 5198 5205 8350395 PMC237917
  115. [115]Li E Brown SL Stupack DG Integrin alpha(v)beta1 is an adenovirus coreceptor J Virol 2001 75 5405 5409 11333925 PMC114949
  116. [116]Bilbao G Gomez-Navarro J Curiel DT Targeted adenoviral vectors for cancer gene therapy Adv Exp Med Biol 1998 451 365 374 365–374. 10026898
  117. [117]Curiel DT Strategies to adapt adenoviral vectors for targeted delivery Ann N Y Acad Sci 1999 886 158 171 158–71. 10667212
  118. [118]Douglas JT Rogers BE Rosenfeld ME Targeted gene delivery by tropism-modified adenoviral vectors Nat Biotechnol 1996 14 1574 1578 9634824
  119. [119]Gu DL Gonzalez AM Printz MA Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: evidence for reduced toxicity and enhanced antitumor activity in mice Cancer Res 1999 59 2608 2614 10363982
  120. [120]Krasnykh V Dmitriev I Mikheeva G Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob J Virol 1998 72 1844 1852 9499035 PMC109474
  121. [121]Li HJ Everts M Pereboeva L Adenovirus tumor targeting and hepatic untargeting by a coxsackie/adenovirus receptor ectodomain anti-carcinoembryonic antigen bispecific adapter Cancer Res 2007 67 5354 5361 17545616
  122. [122]Molinier-Frenkel V Prevost-Blondel A Hong SS The maturation of murine dendritic cells induced by human adenovirus is mediated by the fiber knob domain J Biol Chem 2003 278 37175 37182 12855705
  123. [123]Myhre S Henning P Granio O Decreased immune reactivity towards a knobless, affibody-targeted adenovirus type 5 vector Gene Ther 2007 14 376 381 17036056
  124. [124]Schoggins JW Nociari M Philpott N Falck-Pedersen E Influence of fiber detargeting on adenovirus-mediated innate and adaptive immune activation J Virol 2005 79 11627 11637 16140740 PMC1212603
  125. [125]Nanda A Lynch DM Goudsmit J Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys J Virol 2005 79 14161 14168 16254351 PMC1280229
  126. [126]Rogee S Grellier E Bernard C Influence of chimeric human-bovine fibers on adenoviral uptake by liver cells and the antiviral immune response Gene Ther 2010 17 880 891 20393506
  127. [127]Ostapchuk P Hearing P Pseudopackaging of adenovirus type 5 genomes into capsids containing the hexon proteins of adenovirus serotypes B, D, or E J Virol 2001 75 45 51 11119572 PMC113896
  128. [128]Sumida SM Truitt DM Lemckert AA Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein J Immunol 2005 174 7179 7185 15905562
  129. [129]Waddington SN McVey JH Bhella D Adenovirus serotype 5 hexon mediates liver gene transfer Cell 2008 132 397 409 18267072
  130. [130]Alba R Bradshaw AC Coughlan L Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors Blood 2010 116 2656 2664 20610817 PMC2974579
  131. [131]Kim J Smith T Idamakanti N Targeting adenoviral vectors by using the extracellular domain of the coxsackie-adenovirus receptor: improved potency via trimerization J Virol 2002 76 1892 1903 11799184 PMC135917
  132. [132]Aoki Y Hosaka S Kawa S Kiyosawa K Potential tumor-targeting peptide vector of histidylated oligolysine conjugated to a tumor-homing RGD motif Cancer Gene Ther 2001 8 783 787 11687901
  133. [133]Belousova N Krendelchtchikova V Curiel DT Krasnykh V Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein J Virol 2002 76 8621 8631 12163581 PMC136983
  134. [134]Biermann V Volpers C Hussmann S Targeting of high-capacity adenoviral vectors Hum Gene Ther 2001 12 1757 1769 11560769
  135. [135]Douglas JT Miller CR Kim M A system for the propagation of adenoviral vectors with genetically modified receptor specificities Nat Biotechnol 1999 17 470 475 10331807
  136. [136]Mizuguchi H Koizumi N Hosono T A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob Gene Ther 2001 8 730 735 11406768
  137. [137]Nicklin SA Von Seggern DJ Work LM Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus Mol Ther 2001 4 534 542 11735337
  138. [138]Dmitriev IP Kashentseva EA Curiel DT Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX J Virol 2002 76 6893 6899 12072490 PMC136342
  139. [139]Zakhartchouk A Connors W van KA Tikoo SK Bovine adenovirus type 3 containing heterologous protein in the C-terminus of minor capsid protein IX Virology 2004 320 291 300 15016551
  140. [140]Krasnykh V Belousova N Korokhov N Mikheeva G Curiel DT Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin J Virol 2001 75 4176 4183 11287567 PMC114163
  141. [141]Chillon M Lee JH Fasbender A Welsh MJ Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro Gene Ther 1998 5 995 1002 9813671
  142. [142]Beer SJ Matthews CB Stein CS Poly (lactic-glycolic) acid copolymer encapsulation of recombinant adenovirus reduces immunogenicity in vivo Gene Ther 1998 5 740 746 9747453
  143. [143]Mok H Park JW Park TG Microencapsulation of PEGylated adenovirus within PLGA microspheres for enhanced stability and gene transfection efficiency Pharm Res 2007 24 2263 2269 17929147
  144. [144]Wang D Molavi O Lutsiak ME Poly(D,L-lactic-co-glycolic acid) microsphere delivery of adenovirus for vaccination J Pharm Pharm Sci 2007 10 217 230 17706180
  145. [145]Garcia del BG Hendry J Renedo MJ Irache JM Novo FJ In vivo sustained release of adenoviral vectors from poly(D,L-lactic-co-glycolic) acid microparticles prepared by TROMS J Control Release 2004 94 229 235 14684286
  146. [146]Han SY Lee YJ Jung HI Gene transfer using liposome-complexed adenovirus seems to overcome limitations due to coxsackievirus and adenovirus receptor-deficiency of cancer cells, both in vitro and in vivo Exp Mol Med 2008 40 427 434 18779655 PMC2679272
  147. [147]Fukuhara H Hayashi Y Yamamoto N Improvement of transduction efficiency of recombinant adenovirus vector conjugated with cationic liposome for human oral squamous cell carcinoma cell lines Oral Oncol 2003 39 601 609 12798404
  148. [148]Cao M Deng HX Zhao J Antitumour activity of cationic-liposome-conjugated adenovirus containing the CCL19 [chemokine (C-C motif) ligand 19] gene Biotechnol Appl Biochem 2007 48 109 116 17868025
  149. [149]Zhong Z Shi S Han J Zhang Z Sun X Anionic liposomes increase the efficiency of adenovirus-mediated gene transfer to coxsackie-adenovirus receptor deficient cells Mol Pharm 2010 7 105 115 19968324
  150. [150]Yotnda P Chen DH Chiu W Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses Mol Ther 2002 5 233 241 11863412
  151. [151]Steel JC Cavanagh HM Burton MA Kalle WH Microsphere-liposome complexes protect adenoviral vectors from neutralising antibody without losses in transfection efficiency, in-vitro J Pharm Pharmacol 2004 56 1371 1378 15525443
  152. [152]Aggarwal N HogenEsch H Guo P Biodegradable alginate microspheres as a delivery system for naked DNA Can J Vet Res 1999 63 148 152 10369574 PMC1189535
  153. [153]Bowerstock TL HogenEsch H Suckow M Oral vaccination of animals with antigens encapsulated in alginate microspheres Vaccine 1999 17 1804 1811 10194843
  154. [154]Hilbert AK Fritzsche U Kissel T Biodegradable microspheres containing influenza A vaccine: immune response in mice Vaccine 1999 17 1065 1073 10195616
  155. [155]Mittal SK Aggarwal N Sailaja G Immunization with DNA, adenovirus or both in biodegradable alginate microspheres: effect of route of inoculation on immune response Vaccine 2000 19 253 263 10930680
  156. [156]Periwal SB Speaker TJ Cebra JJ Orally administered microencapsulated reovirus can bypass suckled, neutralizing maternal antibody that inhibits active immunization of neonates J Virol 1997 71 2844 2850 9060640 PMC191409
  157. [157]Lomotan EA Brown KA Speaker TJ Offita PA Aqueous-based microcapsules are detected primarily in gut-associated dendritic cells after oral inoculation of mice Vaccine 1997 15 1959 1962 9413108
  158. [158]Yang D Jones KS Effect of alginate on innate immune activation of macrophages Journal of Biomedical Materials Research Part A 2009 90A 411 418 18523947
  159. [159]Engelhardt JF Ye X Doranz B Wilson JM Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver Proc Natl Acad Sci USA 1994 91 6196 6200 8016137 PMC44165
  160. [160]Fisher KJ Choi H Burda J Chen SJ Wilson JM Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis Virology 1996 217 11 22 8599194
  161. [161]Kochanek S Clemens PR Mitani K A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase Proc Natl Acad Sci USA 1996 93 5731 5736 8650161 PMC39129
  162. [162]Morsy MA Gu M Motzel S An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene Proc Natl Acad Sci USA 1998 95 7866 7871 9653106 PMC20895
  163. [163]Parks R Chen L Anton M A new helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal Proc Natl Acad Sci USA 1996 93 13565 13570 8942974 PMC19345
  164. [164]Schiedner G Morral N Parks RJ Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity Nat Genet 1998 18 180 183 9462752
  165. [165]Morral N Parks RJ Zhou H High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity Hum Gene Ther 1998 9 2709 2716 9874269
  166. [166]Morral N O'Neal W Rice K Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons Proc Natl Acad Sci USA 1999 96 12816 12821 10536005 PMC23112
  167. [167]Roth MD Cheng Q Harui A Helper-dependent adenoviral vectors efficiently express transgenes in human dendritic cells but still stimulate antiviral immune responses J Immunol 2002 169 4651 4656 12370405
  168. [168]Muruve DA Cotter MJ Zaiss AK Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo J Virol 2004 78 5966 5972 15140994 PMC415814
  169. [169]Brunetti-Pierri N Ng T Iannitti DA Improved hepatic transduction, reduced systemic vector dissemination, and long-term transgene expression by delivering helper-dependent adenoviral vectors into the surgically isolated liver of nonhuman primates Hum Gene Ther 2006 17 391 404 16610927
  170. [170]Brunetti-Pierri N Nichols TC McCorquodale S Sustained phenotypic correction of canine hemophilia B after systemic administration of helper-dependent adenoviral vector Hum Gene Ther 2005 16 811 820 16000063
  171. [171]Toietta G Mane VP Norona WS Lifelong elimination of hyperbilirubinemia in the Gunn rat with a single injection of helper-dependent adenoviral vector Proc Natl Acad Sci U S A 2005 102 3930 3935 15753292 PMC554836
  172. [172]Brown BD Shi CX Powell S Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A Blood 2004 103 804 810 14512318
  173. [173]Kim IH Jozkowicz A Piedra PA Oka K Chan L Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector Proc Natl Acad Sci USA 2001 98 13282 13287 11687662 PMC60862
  174. [174]Palmer DJ Ng P Helper-dependent adenoviral vectors for gene therapy Hum Gene Ther 2005 16 1 16 15703484
  175. [175]Bilbao R Reay DP Wu E Comparison of high-capacity and first-generation adenoviral vector gene delivery to murine muscle in utero Gene Ther 2005 12 39 47 15483668
  176. [176]Recchia A Perani L Sartori D Olgiati C Mavilio F Site-specific integration of functional transgenes into the human genome by adeno/AAV hybrid vectors Mol Ther 2004 10 660 670 15451450
  177. [177]Dorigo O Gil JS Gallaher SD Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells J Virol 2004 78 6556 6566 15163748 PMC416543
  178. [178]Ehrhardt A Yant SR Giering JC Somatic integration from an adenoviral hybrid vector into a hot spot in mouse liver results in persistent transgene expression levels in vivo Mol Ther 2007 15 146 156 17164786
  179. [179]King GD Muhammad AK Xiong W High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity J Virol 2008 82 4680 4684 18287240 PMC2293067
  180. [180]Barcia C Jimenez-Dalmaroni M Kroeger KM One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications Mol Ther 2007 15 2154 2163 17895861 PMC2268647
  181. [181]Xiong W Goverdhana S Sciascia SA Regulatable Gutless Adenovirus Vectors Sustain Inducible Transgene Expression in the Brain in the Presence of an Immune Response against Adenoviruses J Virol 2006 80 27 37 16352528 PMC1317549
  182. [182]Thomas CE Schiedner G Kochanek S Castro MG Lowenstein PR Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases Proc Natl Acad Sci USA 2000 97 7482 7487 10840055 PMC16571
  183. [183]Puntel M Muhammad AK Candolfi M A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics J Virol 2010 84 6007 6017 20375153 PMC2876634
  184. [184]Muhammad AK Puntel M Candolfi M Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma Clin Pharmacol Ther 2010 88 204 213 20164833 PMC2908190
  185. [185]Kass-Eisler A Leinwand L Gall J Bloom B Falck-Pedersen E Circumventing the immune response to adenovirus-mediated gene therapy Gene Ther 1996 3 154 162 8867863
  186. [186]Mack CA Song WR Carpenter H Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype Hum Gene Ther 1997 8 99 109 8989999
  187. [187]Mastrangeli A Harvey BG Yao J "Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype Hum Gene Ther 1996 7 79 87 8825871
  188. [188]Parks R Evelegh C Graham F Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration Gene Ther 1999 6 1565 1573 10490766
  189. [189]Appledorn DM Kiang A McBride A Wild-type adenoviruses from groups A–F evoke unique innate immune responses, of which HAd3 and SAd23 are partially complement dependent Gene Ther 2008 15 885 901 18288208
  190. [190]Wang H Li ZY Liu Y Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14 Nat Med 2011 17 96 104 21151137 PMC3074512
  191. [191]Segerman A Atkinson JP Marttila M Adenovirus type 11 uses CD46 as a cellular receptor J Virol 2003 77 9183 9191 12915534 PMC187375
  192. [192]Sirena D Lilienfeld B Eisenhut M The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3 J Virol 2004 78 4454 4462 15078926 PMC387694
  193. [193]Gao W Tamin A Soloff A Effects of a SARS-associated coronavirus vaccine in monkeys Lancet 2003 362 1895 1896 14667748 PMC7112457
  194. [194]Reddy PS Ganesh S Limbach MP Development of adenovirus serotype 35 as a gene transfer vector Virology 2003 311 384 393 12842627
  195. [195]Sakurai F Mizuguchi H Hayakawa T Efficient gene transfer into human CD34+ cells by an adenovirus type 35 vector Gene Ther 2003 10 1041 1048 12776162
  196. [196]Vogels R Zuijdgeest D van RR Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity J Virol 2003 77 8263 8271 12857895 PMC165227
  197. [197]Barouch DH Pau MG Custers JH Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity J Immunol 2004 172 6290 6297 15128818
  198. [198]Shiver JW Emini EA Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors Annu Rev Med 2004 55 355 372 14746526
  199. [199]Sakurai F Nakamura S Akitomo K Transduction properties of adenovirus serotype 35 vectors after intravenous administration into nonhuman primates Mol Ther 2008 16 726 733 18362928
  200. [200]Sakurai F Nakamura SI Akitomo K Adenovirus serotype 35 vector-mediated transduction following direct administration into organs of nonhuman primates Gene Ther 2009 16 297 302 18800152

200 of 224 shown

Cited by

Sorted by citations

See all 185

Metadata

Authors
S. Ahi, Y., S. Bangari, D., & K. Mittal, S.
Venue
Current Gene Therapy
Publisher
Bentham Science Publishers Ltd.
Published
2011-08-01
Volume
11
Issue
4
Pages
307-320
ISSN
1566-5232
DOI
10.2174/156652311796150372
PMC
PMC4009923
Cited by
185
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adenoviral Vector Immunity: Its Implications and Circumvention Strategies. https://app.cochat.ai/papers/10.2174/156652311796150372
The paper
S. Ahi, Y., S. Bangari, D., & K. Mittal, S. (2011). Adenoviral Vector Immunity: Its Implications and Circumvention Strategies. Current Gene Therapy. https://doi.org/10.2174/156652311796150372